COMPANY PROFILE

Exuma Biotech

Explore full profile

Immuno-oncology meets global science and big data - EXUMA Biotechnology

West Palm Beach, United StatesFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Exuma Biotech

Exuma Biotech is a pioneering company in the field of cellular therapies, focusing on developing advanced treatments for challenging solid tumor malignancies. The company operates in the biotechnology sector and serves clients in the healthcare and medical research industries. Exuma Biotech's core business revolves around its proprietary TMR CAR T and CAR TaNK platforms, which harness the power of the immune system to target cancer cells more effectively. These platforms aim to make CAR therapy safer and faster through novel lentivector engineering. The company generates revenue through the development and commercialization of these innovative therapies, as well as through strategic partnerships and alliances. Exuma Biotech's global presence spans from West Palm Beach to Grand Cayman to Shanghai, ensuring a continuous flow of data and innovation.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: West Palm Beach, United States
Employees: 25
Open positions: None listed
Dealroom signal: 37.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Dec 2021	$41M	$164M	Americo Life	↗
SERIES BOther financing	Mar 2020	$19M	$76M	F1 BioVentures · MSD Partners	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Exuma Biotech website traffic

Latest recorded traffic for Exuma Biotech is 1.2K monthly website visits, down 25% over the last three months. Exuma Biotech's team grew 4.2% over the past year.

Latest monthly visits1.2K 3-month web change-25% 1-year team growth+4.2%

Monthly website visitsFeb 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational	1	$9.7M	$12M
DCDCprimeDCprime – We help shape a new era in cancer immunotherapeutics	Leiden, Netherlands	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational
MAMelanoma Research AllianceThe Melanoma Research Alliance exists to accelerate treatment options and find a cure for melanoma	United States	Operational
BPBiosortia PharmaceuticalsBiosortia is working on new drugs from deep access to the chemistry of the microbiome for immuno-oncology & immunological therapeutics	Dublin, United States	Operational
MIMIODxMIODx, a company working on biomarker diagnostics	San Jose, United States	Operational
BBBiond BiologicsInnovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients	Misgav Am, Israel	Operational